SequelSEC

PLIANT THERAPEUTICS, INC. PLRX

Pharmaceutical Preparations · CIK 0001746473 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2025-12-31
Operating income
-$156.37M
Fiscal year ended 2025-12-31
Free cash flow
-$128.71M
Fiscal year ended 2025-12-31

PLIANT THERAPEUTICS, INC. (PLRX) reported revenue of $0 and net income of -$149.34M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from PLIANT THERAPEUTICS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

PLIANT THERAPEUTICS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$0$0$1.58M$9.68M$7.57M$41.82M$57.05M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$156.37M-$228.36M-$184.14M-$127.20M-$97.54M-$41.64M-$1.23M
Net income-$149.34M-$210.30M-$161.34M-$123.32M-$97.26M-$41.53M-$631.00K
Research & development$109.16M$169.31M$127.80M$96.94M$77.55M$66.19M$47.35M
Weighted-average diluted sharesshares 61.37Mshares 60.54Mshares 58.72Mshares 42.02Mshares 35.85Mshares 21.34Mshares 1.62M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0$0
Diluted EPS$-2.43$-3.47$-2.75$-2.94$-2.71$-1.95$-4.22
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$47.22M$59.06M$57.93M$39.95M$27.56M$17.27M$10.93M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

PLIANT THERAPEUTICS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$45.44M$71.19M$63.23M$33.68M$51.66M$50.88M$85.81M
Total assets$225.23M$396.95M$512.15M$350.61M$221.22M$295.53M$119.06M
Current assets$196.45M$362.26M$505.50M$340.31M$209.44M$290.75M$111.90M
Total liabilities$44.02M$92.87M$38.58M$37.27M$22.16M$12.46M$9.08M
Current liabilities$16.36M$33.22M$28.52M$23.91M$16.83M$11.60M$8.17M
Total equity incl. NCI$181.20M$304.08M$473.58M$313.34M$199.06M$283.06M-$76.30M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailable$0$1.98M$2.00M$9.28M$7.05M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$0$30.21M$10.05M$9.93M$0UnavailableUnavailable
Accounts payable$480.00K$5.96M$4.53M$1.58M$2.97M$2.02M$1.25M

Cash flow

PLIANT THERAPEUTICS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$128.34M-$155.50M-$116.36M-$94.63M-$75.44M-$37.27M-$2.75M
Capital expenditures$374.00K$3.85M$921.00K$1.76M$1.95M$1.53M$964.00K
Investing cash flow$134.29M$140.34M-$127.01M-$150.20M$73.70M-$210.87M-$17.93M
Financing cash flow-$31.70M$23.12M$274.40M$226.85M$2.53M$213.21M$45.54M
Net change in cash-$25.74M$7.95M$31.03M-$17.98M$783.00K-$34.92M$24.86M
Stock-based compensation$26.23M$37.63M$44.48M$22.60M$10.44M$3.90M$1.83M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

PLIANT THERAPEUTICS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flow-$128.71M-$159.35M-$117.28M-$96.39M-$77.40M-$38.80M-$3.71M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailable-11654.7%-1313.4%-1288.1%-99.6%-2.2%
FCF marginUnavailableUnavailable-7422.9%-995.3%-1022.1%-92.8%-6.5%
SBC / revenueUnavailableUnavailable2815.4%233.3%137.8%9.3%3.2%
Current ratio12.00x10.91x17.72x14.23x12.44x25.07x13.69x
Revenue YoY growthUnavailable-100.0%-83.7%27.9%-81.9%-26.7%Unavailable
Net marginUnavailableUnavailable-10211.1%-1273.3%-1284.5%-99.3%-1.1%
R&D / revenueUnavailableUnavailable8088.4%1000.9%1024.2%158.3%83.0%
CapEx / revenueUnavailableUnavailable58.3%18.2%25.8%3.7%1.7%
Long-term debt / equity0.00xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PLRX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-11View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2019-12-31

Difference 186275000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.